---

Chief Scientific Officer, Vesper Bio

Almost 30 years ago, Anders Nykjær was part of the pioneering research team that identified the Vps10p-domain receptor sortilin and its interaction with progranulin. Since then, he has led several research centers that have pinpointed the sortilin receptor as an attractive target for the treatment of a variety of disorders, including neurodegenerative disorders.

He has (co-)founded three biotech companies serving as CEO or CSO. He is core group leader of the Danish Research Institute of Translational Neuroscience (DANDRITE), and has served as the Director of the Danish National Research Foundation Center of Excellence, PROMEMO, since 2017. 

“Whatever you become immersed in is the most fascinating question a scientist needs to solve. It doesn’t matter whether it’s lipid metabolism, kidney physiology, or brain disorders; what matters is the deep dive into the unknown.”